Tagged with P

Hong Kong Michael Chan, Senior Vice President of Global Issuer Services for the Hong Kong Exchange (HKEX) highlights the vibrancy and diversity that biotechs have brought to the market, HKEX’s three unique advantages, and how the Hong Kong market aims to adapt to greater demands for diversity.    Hong Kong has a…

Japan A comprehensive list of the new drugs approved by Japan’s Pharmaceutical and Medical Devices Agency (PMDA) in 2019. Made with Visme Infographic Maker  

Mexico A compilation of the top 10 pharmaceutical companies in the Mexican pharmaceutical market based on IQVIA data from February MAT 2020. Four of the top ten companies are Mexican: PISA, Sanfer, Senosiain and Siegfried Rhein.   1. Sanofi Global CEO: Paul Hudson Country Chair: Fernando Sampaio Sanofi has had a…

Roundup Below we highlight some recent developments in pharma and healthcare in the UK, including drug shortages in British intensive care units (ICUs), COVID-19 drug trials, biotech deals and market access developments.   Coronavirus leading to ICU drug shortages In the UK the coronavirus pandemic is leading to shortages of drugs…

Japan Below we highlight the top 10 pharma companies in Japan based on data for 2019 sales of ethical drugs in USD billions. Japanese firms Takeda and Daiichi Sankyo came out on top, with over USD 6 billion in sales revenues.   Made with Visme Infographic Maker

Pharma Faces Mouloud Boukhachab, Pierre Fabre’s managing director for Africa, the Middle East and Turkey, took on the new responsibilities of his current position in March 2020 at the beginning of the coronavirus pandemic. In a recent interview with PharmaBoardroom, Boukhachab outlined the career trajectory that has led him to his current…

Coronavirus IFPMA Director General Thomas B. Cueni shares the outcomes of a recent high level pharma industry media briefing on the search for a COVID-19 treatment; highlighting the unprecedented levels of collaboration being demonstrated as key industry players work towards a common goal.*   Last week, high-level representatives from seven companies…

USA Carol Lynch, president of Sandoz US and head of Sandoz North America, recently spoke exclusively to PharmaBoardroom about how her diverse global experiences in innovative biopharma and biosimilars are informing her leadership strategy in the US generics space. Lynch also outlines how greater uptake of biosimilar medicines can be fostered…

China Alphamab Oncology and I-Mab Biopharma, two of China’s fastest-growing biotech firms, both bolstered by recent successful IPOs, are increasingly adapting their portfolio strategies to launch products on the large but challenging domestic Chinese market.   I-Mab: Observing Competitors and Staying Flexible I-Mab already has a fairly advanced China portfolio, with…

China Established in December 2012, in less than a decade, Chinese biotech Junshi Biosciences has already transformed itself into a publicly-listed commercial company with a successful USD 450 million IPO on the Hong Kong Stock Exchange and their first product, toripalimab, being the first anti-PD-1 monoclonal antibody self-developed by a Chinese…

Korea Founder, CEO and CTO Dr Chae-Ok Yun introduces GeneMedicine, a pioneer of the oncolytic virus approach in gene therapy. Dr Yun outlines the significance of a recent capital injection, ongoing clinical trials, and the complementarity of oncolytic virus with other gene therapies such as CAR-T.   Oncolytic virus is not…

China PharmaBoardroom caught up with Alphamab Oncology’s founder, chairman and CEO Dr Xu Ting again 16 months after our last interview to hear about their successful HKEX IPO in December 2019, his commercial expectations for their flagship PD-1/PD-L1 product, and the impact of COVID-19 on their operations.   The core business…